Open label extension study for monitoring long-term safety in patients with Myoclonic Astatic Epilepsy (Doose-Syndrome) receiving Fenfluramine as add-on therapy
Latest Information Update: 06 Oct 2021
At a glance
- Drugs Fenfluramine (Primary)
- Indications Myoclonic epilepsies
- Focus Adverse reactions; Therapeutic Use
- Acronyms FFA-MAE-EXT
- 05 Oct 2021 Planned number of patients changed from 20 to 10.
- 26 Mar 2021 New trial record